摘要
目的:探讨中成药糖脉康颗粒与α-糖苷酶抑制剂伏格列波糖(倍欣)对大鼠1型糖尿病模型的降糖效果,确定上述两种药物是否可以作为1型糖尿病的阳性对照药物。方法:采用四氧嘧啶腹腔注射2次制备SD(Sprague Dawley)大鼠1型糖尿病模型,灌胃给药15天,给药期内测定空腹血糖变化。结果:与模型组相比,糖脉康能够显著降低大鼠体内的血糖(P<0.05),倍欣也能够显著降低模型大鼠的血糖(P<0.05),而中药糖脉康降低血糖的效能比倍欣更强(P>0.05)。结论:四氧嘧啶制备的SD大鼠糖尿病1型糖尿病模型在给药期间能保持稳定性,糖脉康与倍欣均有明显的降糖效果,可以作为1型糖尿病研究的阳性对照药。
Objective：To compare the Chinese traditional medicines Tangmaikang with ct-amylase inhibitor voglibose in the treatment for type Ⅰ diabetic rat models,and to determine whether it can be used as positive treatments drug.Methods：type Ⅰ diabetic rat models were made by aUoxan intraperitoneal injection with two times.Oral administration period sustained for 15 d,the fasting blood glucose was measured during the administration.Results：Compared with the control group,Tangmaikang was able to significantly reduce the blood sugar of rats （P〈0.05）,otherwise, voglibose could significantly reduce the blood sugar （P〈0.05）.Conclusion：During the administration, type Ⅰ diabetic rat models can maintain stability.Tangmaikang and voglibose can obviously reduce the blood sugar as positive control drug in the treatment of type Ⅰ diabetic rat models.
出处
《现代医药卫生》
2009年第8期1123-1124,共2页
Journal of Modern Medicine & Health
关键词
糖脉康
倍欣
1型糖尿病模型
Tangmaikang
Voglibese
type Ⅰ diabetic rat models
